Correlation analysis of obesity phenotypes with leptin and adiponectin.

Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited Medium: Internet ISSN: 2045-2322 (Electronic) Linking ISSN: 20452322 NLM ISO Abbreviation: Sci Rep Subsets: MEDLINE

Original Publication: London : Nature Publishing Group, copyright 2011-

Insulin Resistance* ; Metabolic Syndrome*/metabolism ; Obesity, Metabolically Benign*; Humans ; Adiponectin ; Body Mass Index ; Cholesterol, LDL ; Cross-Sectional Studies ; Cytokines ; Leptin ; Obesity/metabolism ; Phenotype ; Triglycerides

Obesity can be categorized as metabolically healthy obesity (MHO) and metabolically unhealthy obesity (MUO). However, individuals with MHO are characterized by the absence of metabolic syndrome (MS) and appear to have lower inflammation levels compared to MUO. This study aimed to investigate the association of obesity phenotypes with leptin (LEP) and adiponectin (ADP). According to the inclusion and exclusion criteria, we selected 178 subjects from the previous cross-sectional survey. Based on the body mass index (BMI) and diagnostic criteria of MS, we divided the individuals into three groups, including healthy control group (HC group), metabolically healthy obesity group (MHO group) and metabolically unhealthy obesity group (MUO group). The concentrations of LEP and ADP in serum were measured, and the association of these two cytokines with different obesity phenotypes were subsequently analyzed. Compared to both the HC and MHO groups, the MUO group showed significantly higher BMI, waist circumference (WC), waist-hip ratio (WHR), triglyceride (TG), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), fasting plasma glucose (FPG), homeostasis model assessment of insulin resistance (Homa-IR) and blood pressure (P < 0.05). In contrast, serum high-density lipoprotein cholesterol (HDL-C) was notably lower in the MUO group (P < 0.05). ADP was found to have a positive correlation with systolic blood pressure (SBP) and a negative correlation with FPG in the MHO group. In the MUO group, LEP demonstrated a positive correlation with fasting insulin (FINS) and Homa-IR, while ADP showed a positive correlation with TC and SBP. Linear regression analysis further indicated that SBP (β = 0.234, P = 0.043), TG (β = - 0.292, P = 0.001) and LDL-C (β = 0.626, P = 0.000) were independently correlated with ADP, and BMI (β = 0.398, P = 0.002) was independently correlated with LEP in obese individuals. In conclusion, ADP and LEP were closely related with glucose and lipid metabolism in obese individuals, these two cytokines might play critical roles in obesity-associated metabolic disorders.
(© 2023. Springer Nature Limited.)

Curr Opin Lipidol. 2007 Jun;18(3):263-70. (PMID: 17495599)
Circulation. 2009 Oct 20;120(16):1640-5. (PMID: 19805654)
Lancet Diabetes Endocrinol. 2013 Oct;1(2):152-62. (PMID: 24622321)
Endocrine. 2021 Sep;73(3):580-587. (PMID: 34023981)
Regul Pept. 2008 Aug 7;149(1-3):26-31. (PMID: 18453013)
Endocr Rev. 2020 May 1;41(3):. (PMID: 32128581)
Life (Basel). 2021 Dec 07;11(12):. (PMID: 34947881)
Endocrinology. 1998 Feb;139(2):551-8. (PMID: 9449624)
J Clin Invest. 2019 Oct 1;129(10):3978-3989. (PMID: 31524630)
Curr Opin Lipidol. 2010 Feb;21(1):38-43. (PMID: 19915462)
Nutrients. 2016 Jun 01;8(6):. (PMID: 27258304)
Nature. 2006 Dec 14;444(7121):860-7. (PMID: 17167474)
Int J Clin Pract. 2021 Nov;75(11):e14727. (PMID: 34383387)
Int J Med Sci. 2016 Jan 01;13(1):25-38. (PMID: 26816492)
Trends Pharmacol Sci. 2015 Jul;36(7):461-70. (PMID: 26022934)
Nat Rev Endocrinol. 2013 Jan;9(1):13-27. (PMID: 23165161)
J Hypertens. 2009 Jul;27(7):1370-6. (PMID: 19412132)
Diabetes Care. 2006 Jun;29(6):1357-62. (PMID: 16732021)
Iran J Public Health. 2019 Jun;48(6):1106-1115. (PMID: 31341853)
Exp Ther Med. 2019 Jan;17(1):791-797. (PMID: 30651864)
Lancet. 2011 Feb 12;377(9765):557-67. (PMID: 21295846)
Metabolism. 2010 Mar;59(3):424-9. (PMID: 19846168)
Obes Rev. 2014 Jun;15(6):504-15. (PMID: 24661566)
Mediators Inflamm. 2012;2012:456456. (PMID: 23091306)
J Obes. 2015;2015:178526. (PMID: 25838943)
Annu Rev Immunol. 2011;29:415-45. (PMID: 21219177)
J Clin Endocrinol Metab. 2004 Jun;89(6):2665-71. (PMID: 15181039)
Appetite. 2017 Jan 1;108:477-482. (PMID: 27838444)
Metabolism. 2015 Jan;64(1):24-34. (PMID: 25199978)
J Clin Endocrinol Metab. 2015 Nov;100(11):4172-80. (PMID: 26401592)
Eur J Endocrinol. 2006 Jul;155(1):167-76. (PMID: 16793964)
Metabolism. 2019 Mar;92:51-60. (PMID: 30458177)
J Obstet Gynaecol. 2012 Jan;32(1):73-7. (PMID: 22185543)
Rev Endocr Metab Disord. 2013 Sep;14(3):219-27. (PMID: 23928851)
Curr Pharm Des. 2014;20(4):652-8. (PMID: 23688014)
Diabetes Metab Syndr Obes. 2020 Aug 26;13:3099-3112. (PMID: 32904655)
Exp Ther Med. 2014 Apr;7(4):1023-1027. (PMID: 24669271)
N Engl J Med. 2008 Nov 13;359(20):2105-20. (PMID: 19005195)
Rev Diabet Stud. 2019;15:83-94. (PMID: 31904760)
Circ J. 2004 Nov;68(11):975-81. (PMID: 15502375)

0 (Adiponectin)
0 (Cholesterol, LDL)
0 (Cytokines)
0 (Leptin)
0 (Triglycerides)
0 (ADIPOQ protein, human)
0 (LEP protein, human)

Date Created: 20231018 Date Completed: 20231030 Latest Revision: 20231122

20231215

PMC10584881

10.1038/s41598-023-43550-8

37853077